Abstract
AbstractAbstract 3710 Background:Relapsed/refractory DLBCL has poor prognosis in the rituximab era. Pts who failed Rituximab-containing initial chemo regimen within 12 mo do particularly poorly. (ORR 46–51% vs. 83–88%, EFS 20% vs. 45% at three years). Novel salvage therapies to overcome chemo resistance and maintain remission in post transplant setting are needed.The immunomodulatory agent lenalidomide has demonstrated direct tumoricidal and antiproliferative effects in lymphoma and clinical activity and safety in multiple phase II studies in aggressive NHL. Methods:We are conducting a phase I/II trial combining lenalidomide with RICE (rituximab, ifosfamide, carboplatin and etoposide) (RICER) as a salvage regimen in first relapse or primary refractory DLBCL. Four dose levels of lenalidomide are being evaluated in Phase I part of the study: 10mg, 15mg, 20mg, and 25mg given for 7 days (days 1–7) together with RICE. After three cycles of RICER patients with chemo sensitive disease proceed to stem cell collection (off 3rdRICE) and consolidation with BEAM followed by autologous SCT (ASCT). Patients who recover from ASCT toxicities within 90 days are started on maintenance with lenalidomide 25mg daily for 21 days every 28 days for 12 months. Results:13 patients have been enrolled. DLT was not seen at 25 mg (last dose level tested) of lenalidomide during the salvage part of RICER. No unexpected toxicities were observed by adding lenalidomide to RICE. Grade 3 and 4 hematologic toxicities were comparable to RICE alone and resolved appropriately and planned dose density and dose intensity of RICER were preserved. One episode of febrile neutropenia occurred during RICER administration. No new DVT’s occurred during lenalidomide administration either in salvage or in post ASCT maintenance part of the trial. Stem cell collection was successful in all but one patient. So far seven patients have completed ASCT and five patients were able to start on maintenance lenalidomide post transplantation. No unusual toxicities were observed in the peritransplantation period and there was no delay in engraftment: median days to ANC of >500 is 11, and to plts over 20K/mL is 11. In the maintenance post ASCT there was no infection but routine dose reductions were required because of myelotoxicity. Conclusions:1.Adding lenalidomide to RICE (RICER) is feasible salvage regimen with no increased toxicity.2.PET-CR rate is promising in this very refractory DLBCL population.3.While it is premature for any definitive conclusions regarding feasibility of maintenance lenalidomide in post transplant setting, trial is ongoing with expansion in additional institutions.Table 1Patient characteristicsNumber of patients13Male/female10/3Median age64 (47–75)Disease characteristicNumber of patientsStage at relapse III-IV8 out of 13Relapse IPI6Low, low intermediate7Intermediate high, highPrimary refractory6Relapse <12 months of initial therapy5Relapse >12 mo of initial therapy2Rituximab used with initial therapy13Initial therapy9R-CHOP3R-HCVAD/R-MA1R-CODOX-M/IVACOverall response (OR)9Complete response (CR)8Partial response (PR)1Stable disease (SD)3Progression of disease (PD)1Auto SCT characteristicsStem cell harvest5.24 mln/kg (range 3.37–12.8mln/kg)Median time to platelets recovery to 20,000/mL without transfusional support12 days (range 7 to 14)Median time to ANC >500/mL11 days (range 9 to 11) Disclosures:Feldman:allos: Speakers Bureau; merck: Speakers Bureau; celgene: Speakers Bureau; seattle genetics: Speakers Bureau. Off Label Use: Lenalidomide in combination with chemotherapy as salvage regimen for DLBCL. Mato:Celgene: Speakers Bureau; seattle genetics: Speakers Bureau; genentech: Speakers Bureau; millennium: Speakers Bureau. Goldberg:Eisai: Speakers Bureau. Vesole:Celgene Corp.: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Millennium: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau. Siegel:Celgene: Advisory Board Other, Honoraria, Speakers Bureau; Millennium Pharma: Advisory Board, Advisory Board Other, Honoraria, Speakers Bureau; Onyx: Advisory Board, Advisory Board Other, Honoraria, Speakers Bureau; Merck: Advisory Board, Advisory Board Other, Honoraria, Speakers Bureau. Goy:Milennium: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity’s Board of Directors or advisory committees; Seattle Genetics: Membership on an entity’s Board of Directors or advisory committees; Pharmacyclics: Membership on an entity’s Board of Directors or advisory committees; J & J: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Membership on an entity’s Board of Directors or advisory committees.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.